Expert Interview
A Look at PDS Bio's PDS101 immunotherapy in HPV16+ Cancers
Ticker(s): PDSBInstitution: The University of Kansas Cancer Center
- Assistant Professor, Medical Oncology at The University of Kansas.
- Manages ~30 Head and Neck Squamous Cell Cancer Patients.
- Focus on Drug Discovery, Delivery & Experimental Therapeutics.
Roughly how many patients do you treat with HNSCC?
Added By: c_adminHow would you rate your level of excitement for this agent (10 being extremely excited)?
Added By: c_adminHow important do you think the other agents in the triple combination are (The IL-12 PDS0301 and Bintrafusp Alfa) to achieving good clinical outcomes?
Added By: userbdcc81a6What other agents in development for HNSCC are you most excited about? Do you think these could be competitive to PDS0101 or complimentary?
Added By: userbdcc81a6Recently MD Anderson presented early results of PDS0101 in combination with chemotherapy in cervical cancer, showing elimination or circulating tumor DNA and t-cell infiltration into the tumor. How important are these biomarkers? Are there important markers that you would like to see in HNSCC that would be predictive of efficacy?
Added By: userbdcc81a6Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
